59 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals for, and clinical utility of GOHIBIC (vilobelimab … disbursements of its legal counsel. We estimate that the total expenses for the offering, excluding any commissions or expense reimbursement payable
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 24
Leerink Partners LLC
4:55pm
or governmental charges of whatever nature (including any amounts that result from the payment of fees, compensation or reimbursement of costs contemplated
6-K
EX-99.1
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
and reimbursement for, estimated returns and return accruals for, and clinical utility of GOHIBIC (vilobelimab) in its approved or authorized indication
6-K
EX-99.1
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
or our other product candidates; our expectations regarding the size of the patient populations for, market opportunity for, coverage and reimbursement
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
regarding the size of the patient populations for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals
6-K
EX-99.1
w2z8g7g t4geur3s
21 May 24
Report of Foreign Private Issuer
4:15pm
6-K
EX-99.2
4eb81j9impv7pipjkq
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
EX-99.3
29dc1dr
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
EX-99.1
3g1hzcxt31hw 8iu9l0
21 Mar 24
Corporate Presentation March 2024
5:00pm
6-K
EX-99.1
geo42
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
6-K
EX-99.1
xnp5cm83695 gyiomp30
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
6-K
EX-99.1
8vy822v354nex26
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.2
0bq yjqiowav25shzu
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.1
iahukspohrla1fx
6 Nov 23
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
8:00am
6-K
EX-99.2
bijedn0 z2p7fnsey
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.3
5s4xr xh5
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.1
eczqgbaz 34xap
11 Sep 23
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
8:45am
6-K
EX-99.1
29qbq6wlld
30 Aug 23
Current report (foreign)
8:00am